{"id":"W3016102083","doi":"10.1016/j.cjco.2020.04.002","title":"Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome","year":2020,"lang":"en","type":"review","venue":"CJC Open","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Trillium Health Centre; Université de Montréal; University of Alberta; Canadian VIGOUR Centre; University of Toronto; Hamilton Health Sciences; Montreal Heart Institute; Canadian Heart Research Centre; St. Michael's Hospital","funders":"Duke Clinical Research Institute; American Regent; Bristol-Myers Squibb Canada; Esperion Therapeutics; GlaxoSmithKline; HLS Therapeutics; Bayer; Servier; University of Toronto; Novo Nordisk; Daiichi-Sankyo; Bayer Canada; Regeneron Pharmaceuticals; HDL Therapeutics; Valeant Pharmaceuticals International; AstraZeneca Canada; Actelion Pharmaceuticals; York University; Pfizer; Heart and Stroke Foundation of Canada; Novartis; Sanofi; Merck; Boehringer Ingelheim; Amgen; CSL Behring; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Acute coronary syndrome; Medicine; Ezetimibe; Residual risk; Eicosapentaenoic acid; Type 2 diabetes; Proprotein convertase; Clinical trial; Statin; Secondary prevention; Internal medicine; Ticagrelor; Pioglitazone; Pharmacology; Diabetes mellitus; Cholesterol; Endocrinology; Lipoprotein; Myocardial infarction; Fatty acid; Polyunsaturated fatty acid; Biochemistry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004683123,0.001016169,0.002548775,0.003458886,0.0004175524,0.003114236,0.001615424,0.002675309,0.01043944],"category_scores_gemma":[0.01314745,0.0004581679,0.002590127,0.002880595,0.0006802846,0.002486348,0.001482246,0.003917297,0.002598172],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001443779,"about_ca_system_score_gemma":0.005108334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002576891,"about_ca_topic_score_gemma":0.004800987,"domain_scores_codex":[0.9972596,0.000916417,0.0006810185,0.0002064099,0.0008063982,0.0001301621],"domain_scores_gemma":[0.9895108,0.006063144,0.001044726,0.0002204733,0.002790061,0.0003707151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0004197297,0.0001218596,0.0003827102,0.07805775,0.0009735001,0.0002099455,0.0001407565,0.0002084737,0.0003271198,0.004189217,0.08997736,0.8249916],"study_design_scores_gemma":[0.0001570135,0.0002116481,0.001481827,0.1059993,0.002288387,0.0004713694,0.0001134537,0.0001184427,0.0001456244,0.003075198,0.885909,0.00002893785],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002005783,0.9888942,0.0002797139,0.005253702,0.002736451,0.00004011895,0.0001730575,0.0000270044,0.002395352],"genre_scores_gemma":[0.001624684,0.9900445,0.0009539518,0.004449835,0.002018315,0.00005317935,0.000244104,0.000009311836,0.0006021785],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01043944,"threshold_uncertainty_score":0.03492337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0648228337220232,"score_gpt":0.3745882926936696,"score_spread":0.3097654589716464,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}